Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact

Citations to this article

Direct activation of PP2A for the treatment of tyrosine kinase inhibitor–resistant lung adenocarcinoma
Rita Tohmé, … , Jaya Sangodkar, Goutham Narla
Rita Tohmé, … , Jaya Sangodkar, Goutham Narla
Published February 21, 2019
Citation Information: JCI Insight. 2019;4(4):e125693. https://doi.org/10.1172/jci.insight.125693.
View: Text | PDF
Research Article Oncology Therapeutics Article has an altmetric score of 19

Direct activation of PP2A for the treatment of tyrosine kinase inhibitor–resistant lung adenocarcinoma

  • Text
  • PDF
Abstract

Although tyrosine kinase inhibitors (TKIs) have demonstrated significant efficacy in advanced lung adenocarcinoma (LUAD) patients with pathogenic alterations in EGFR, most patients develop acquired resistance to these agents via mechanisms enabling the sustained activation of the PI3K and MAPK oncogenic pathways downstream of EGFR. The tumor suppressor protein phosphatase 2A (PP2A) acts as a negative regulator of these pathways. We hypothesize that activation of PP2A simultaneously inhibits the PI3K and MAPK pathways and represents a promising therapeutic strategy for the treatment of TKI-resistant LUAD. After establishing the efficacy of small molecule activators of PP2A (SMAPs) in a transgenic EGFRL858R model and TKI-sensitive cell lines, we evaluated their therapeutic potential in vitro and in vivo in TKI-resistant models. PP2A activation resulted in apoptosis, significant tumor growth inhibition, and downregulation of PI3K and MAPK pathways. Combination of SMAPs and TKI afatinib resulted in an enhanced effect on the downregulation of the PI3K pathway via degradation of the PP2A endogenous inhibitor CIP2A. An improved effect on tumor growth inhibition was observed in a TKI-resistant xenograft mouse model treated with a combination of both agents. These collective data support the development of PP2A activators for the treatment of TKI-resistant LUAD.

Authors

Rita Tohmé, Sudeh Izadmehr, Sai Gandhe, Giancarlo Tabaro, Sanjay Vallabhaneni, Ava Thomas, Neal Vasireddi, Neil S. Dhawan, Avi Ma’ayan, Neelesh Sharma, Matthew D. Galsky, Michael Ohlmeyer, Jaya Sangodkar, Goutham Narla

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 Total
Citations: 4 10 6 8 5 6 6 45
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (45)

Title and authors Publication Year
Small molecule modulators of B56-PP2A restore 4E-BP function to suppress eIF4E-dependent translation in cancer cells
Michelle A. Lum, Kayla A. Jonas, Shreya Parmar, Adrian R. Black, Caitlin M. O'Connor, Stephanie Dobersch, Naomi Yamamoto, Tess M Robertson, Aidan Schutter, Miranda Giambi, Rita A. Avelar, Analisa DiFeo, Nicholas T. Woods, Sita Kugel, Goutham Narla, Jennifer D. Black
Journal of Clinical Investigation 2025
The off-target effect of loratadine triggers autophagy-mediated apoptosis in lung adenocarcinoma cells by deactivating JNK, p38, and STAT3 signaling through both PP2A-dependent and independent pathways
Chien MH, Hung WY, Lai TC, Tsai CH, Lee KL, Hsieh FK, Lee WJ, Chang JH
International Journal of Molecular Medicine 2025
PP2A attenuates thoracic aneurysm and dissection in mouse models of Marfan syndrome
Zhou X, Xu Q, Hu X, Klenotic PA, Valdivia A, Leshnower BG, Dong N, Narla G, Lin Z
Hypertension (Dallas, Tex. : 1979) 2025
Small Molecule Activators of Protein Phosphatase 2A Exert Global Stabilising Effects on the Scaffold PR65.
Naqvi MM, Zacharopoulou M, Saha S, Banerjee A, Yilmaz ZS, Sunderlikova V, Johnson CM, Kumita JR, Yang SH, Gordon R, Ohlmeyer M, Tans S, Gur M, Bahar I, Itzhaki LS
bioRxiv : the preprint server for biology 2025
Altering phosphorylation in cancer through PP2A modifiers.
Johnson H, Narayan S, Sharma AK
Cancer Cell International 2024
Integrated stress response plasticity governs normal cell adaptation to chronic stress via the PP2A-TFE3-ATF4 pathway
Avelar RA, Gupta R, Carvette G, da Veiga Leprevost F, Colina J, Teitel J, Nesvizhskii AI, O\u2019Connor CM, Hatzoglou M, Shenolikar S, Arvan P, Narla G, DiFeo A
Research square 2024
Influence of point mutations on PR65 conformational adaptability: Insights from molecular simulations and nanoaperture optical tweezers
Banerjee A, Mathew S, Naqvi MM, Yilmaz SZ, Zacharopoulou M, Doruker P, Kumita JR, Yang SH, Gur M, Itzhaki LS, Gordon R, Bahar I
Science Advances 2024
KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development
Tinsley SL, Shelley RA, Mall GK, Chianis ER, Dhiman A, Baral G, Kothandaraman H, Thoma MC, Daniel CJ, Lanman NA, di Magliano MP, Narla G, Solorio L, Dykhuizen EC, Sears RC, Allen-Petersen BL
2024
NOS2 and COX-2 Co-Expression Promotes Cancer Progression: A Potential Target for Developing Agents to Prevent or Treat Highly Aggressive Breast Cancer
Coutinho LL, Femino EL, Gonzalez AL, Moffat RL, Heinz WF, Cheng RY, Lockett SJ, Rangel MC, Ridnour LA, Wink DA
International journal of molecular sciences 2024
SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma
Luk IS, Bridgwater CM, Yu A, Boila LD, Yáñez-Bartolomé M, Lampano AE, Hulahan TS, Boukhali M, Kathiresan M, Macarulla T, Kenerson HL, Yamamoto N, Sokolov D, Engstrom IA, Sullivan LB, Lampe PD, Cooper JA, Yeung RS, Tian TV, Haas W, Saha SK, Kugel S
Science Translational Medicine 2024
Resveratrol Induces Myotube Development by Altering Circadian Metabolism via the SIRT1-AMPK-PP2A Axis
Avital-Cohen N, Chapnik N, Froy O
Cells 2024
Integrated stress response plasticity governs normal cell adaptation to chronic stress via the PP2A-TFE3-ATF4 pathway.
A Avelar R, Gupta R, Carvette G, da Veiga Leprevost F, Jasti M, Colina J, Teitel J, Nesvizhskii AI, O'Connor CM, Hatzoglou M, Shenolikar S, Arvan P, Narla G, DiFeo A
Cell death and differentiation 2024
KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development.
Tinsley SL, Chianis ERD, Shelley RA, Mall GK, Dhiman A, Baral G, Kothandaraman H, Thoma MC, English IA, Daniel CJ, Acosta LCS, Solorio L, Atallah Lanman N, Pasca di Magliano M, Narla G, Dykhuizen EC, Sears RC, Allen-Petersen BL
Oncogene 2024
Novel PP2A-Activating Compounds in Neuroblastoma
Nazam N, Bownes LV, Julson JR, Quinn CH, Erwin MH, Marayati R, Markert HR, Shirley S, Stewart JE, Yoon KJ, Aye J, Ohlmeyer M, Beierle EA
Cancers 2024
PP2A Modulation Overcomes Multidrug Resistance via Mitochondrial Permeability Transition Pore-Dependent Apoptosis Induction in CLL
Kallesh Jayappa, Caroline Farrington, Vicki L. Gordon, Shekhar Saha, Christopher Morris, Krista M. Isaac, Mark Kester, Timothy Bender, Michael E. Williams, Craig A. Portell, Michael Weber, Goutham Narla
Journal of Clinical Investigation 2023
Small-Molecule–Mediated Stabilization of PP2A Modulates the Homologous Recombination Pathway and Potentiates DNA Damage-Induced Cell Death
Avelar RA, Armstrong AJ, Carvette G, Gupta R, Puleo N, Colina JA, Joseph P, Sobeck AM, O'Connor CM, Raines B, Gandhi A, Dziubinski ML, Ma DS, Resnick K, Singh S, Zanotti K, Nagel C, Waggoner S, Thomas DG, Skala SL, Zhang J, Narla G, DiFeo A
Molecular cancer therapeutics 2023
The Effects of Protein Phosphatase 2A Activation with Novel Tricyclic Sulfonamides on Hepatoblastoma
Bownes LV, Julson JR, Quinn CH, Hutchins SC, Erwin MH, Markert HR, Stewart JE, Mroczek-Musulman E, Aye J, Yoon KJ, Ohlmeyer M, Beierle EA
Journal of Pediatric Surgery 2023
The evolution of small molecule enzyme activators
Dow LF, Case AM, Paustian MP, Pinkerton BR, Simeon P, Trippier PC
2023
Influence of Point Mutations on PR65 Conformational Adaptability: Insights from Nanoaperture Optical Tweezer Experiments and Molecular Simulations.
Bahar I, Banerjee A, Mathew S, Naqvi M, Yilmaz S, Zachoropoulou M, Doruker P, Kumita J, Yang SH, Gur M, Itzhaki L, Gordon R
Research square 2023
Protein Phosphatase 2A Activation Promotes Heart Transplant Acceptance in Mice
Zhou X, Xu Q, Li W, Dong N, Stomberski C, Narla G, Lin Z
Transplantation 2023
Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma
L Bownes, R Marayati, C Quinn, A Beierle, S Hutchins, J Julson, M Erwin, J Stewart, E Mroczek-Musulman, M Ohlmeyer, J Aye, K Yoon, E Beierle
Cancers 2022
PP2A and cancer epigenetics: a therapeutic opportunity waiting to happen
S Tinsley, B Allen-Petersen
2022
Therapeutic targeting of “undruggable” MYC
V Llombart, M Mansour
EBioMedicine 2022
Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A
Narayan S, Raza A, Mahmud I, Koo N, Garrett TJ, Law ME, Law BK, Sharma AK
iScience 2022
Potential of phenothiazines to synergistically block calmodulin and reactivate PP2A in cancer cells
Manoharan GB, Okutachi S, Abankwa D
PloS one 2022
Fbxo45‐mediated NP‐STEP46 degradation via K6‐linked ubiquitination sustains ERK activity in lung cancer
Wang Q, Xu C, Cai R, An W, Yuan H, Xu M
Molecular Oncology 2022
GSK3β is a critical, druggable component of the network regulating the active NOTCH1 protein and cell viability in CLL
De Falco F, Rompietti C, Sorcini D, Esposito A, Scialdone A, Baldoni S, Del Papa B, Adamo FM, Silva Barcelos EC, Dorillo E, Stella A, Di Ianni M, Screpanti I, Sportoletti P, Rosati E
Cell Death and Disease 2022
LCK‐Mediated RIPK3 Activation Controls Double‐Positive Thymocyte Proliferation and Restrains Thymic Lymphoma by Regulating the PP2A‐ERK Axis
Hwang S, Ha Y, Koo G, Noh H, Lee A, Kim B, Hong SM, Morgan MJ, Eyun S, Lee D, Roe J, Lee Y, Kim Y
Advanced Science 2022
PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition–Dependent GSK-3β–Mediated c-Myc and Pim-1 Proteasomal Degradation
M Scarpa, P Singh, CM Bailey, JK Lee, S Kapoor, RG Lapidus, S Niyongere, J Sangodkar, Y Wang, D Perrotti, G Narla, MR Baer
Molecular cancer therapeutics 2021
Drug‐like sphingolipid SH‐BC‐893 opposes ceramide‐induced mitochondrial fission and corrects diet‐induced obesity
V Jayashankar, E Selwan, SE Hancock, A Verlande, MO Goodson, KH Eckenstein, G Milinkeviciute, BM Hoover, B Chen, AG Fleischman, KS Cramer, S Hanessian, S Masri, N Turner, AL Edinger
EMBO Molecular Medicine 2021
Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents
DL Brautigan, C Farrington, G Narla
Clinical Science 2021
Allosteric activation of PP2A inhibits experimental abdominal aortic aneurysm
X Zhou, C Zhang, F Xie, W Wei, R Li, Q Xu, Y Wang, PA Klenotic, G Narla, N Dong, Z Lin
Clinical Science 2021
Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer
K Sahin, E Shah, G Ferguson, C Molloy, P Croft, S Hayes, A Hudson, E Colvin, H Kamitakahara, R Harvie, C Hasovits, T Khan, P Duijf, V Howell, Y He, E Bolderson, J Hooper, S Lakhani, D Richard, K OByrne, M Adams
Cancers 2021
Selective PP2A Enhancement through Biased Heterotrimer Stabilization
D Leonard, W Huang, S Izadmehr, CM OConnor, DD Wiredja, Z Wang, N Zaware, Y Chen, DM Schlatzer, J Kiselar, N Vasireddi, S Schüchner, AL Perl, MD Galsky, W Xu, DL Brautigan, E Ogris, DJ Taylor, G Narla
Cell 2020
Mutations in the RNA Splicing Factor SF3B1 Promote Tumorigenesis through MYC Stabilization
Z Liu, A Yoshimi, J Wang, H Cho, SC Lee, M Ki, L Bitner, T Chu, H Shah, B Liu, AR Mato, P Ruvolo, G Fabbri, L Pasqualucci, O Abdel-Wahab, R Rabadan
Cancer Discovery 2020
Perphenazine exerts antitumor effects on HUT78 cells through Akt dephosphorylation by protein phosphatase 2A
S Tsuji, N Kohyanagi, T Mizuno, T Ohama, K Sato
Oncology Letters 2020
Direct Activation of Protein Phosphatase 2A (PP2A) by Tricyclic Sulfonamides Ameliorates Alzheimer’s Disease Pathogenesis in Cell and Animal Models
H Wei, H Zhang, X Wang, J Xie, D An, L Wan, J Wang, Y Zeng, , J Westermarck, Y Lu, M Ohlmeyer, R Liu
Neurotherapeutics 2020
Loss of HIF1A From Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53 to Promote Invasion and Metastasis
A Tiwari, K Tashiro, A Dixit, A Soni, K Vogel, B Hall, I Shafqat, J Slaughter, N Param, A Le, E Saunders, U Paithane, G Garcia, AR Campos, J Zettervall, M Carlson, TK Starr, Y Marahrens, AJ Deshpande, C Commisso, PP Provenzano, A Bagchi
Gastroenterology 2020

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations


W Yang, N Chen, L Li, X Chen, X Liu, Y Zhang, J Cui
Lung Cancer: Targets and Therapy 2020
Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers
CC Farrington, E Yuan, S Mazhar, S Izadmehr, L Hurst, BL Allen-Petersen, M Janghorban, E Chung, G Wolczanski, M Galsky, R Sears, J Sangodkar, G Narla
The Journal of biological chemistry 2019
Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration
AR Clark, M Ohlmeyer
Pharmacology & Therapeutics 2019
Protein phosphatase 2A (PP2A): a key phosphatase in the progression of chronic obstructive pulmonary disease (COPD) to lung cancer
CP Nader, A Cidem, NM Verrills, AJ Ammit
Respiratory Research 2019
Protein phosphatase 2A controls ongoing DNA replication by binding to and regulating cell division cycle 45 (CDC45)
AL Perl, CM O'Connor, P Fa, FM Pozo, J Zhang, Y Zhang, G Narla
The Journal of biological chemistry 2019
PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer
M Remmerie, V Janssens
Frontiers in Oncology 2019
Two-hybrid screening of FAM13A protein partners in lung epithelial cells
M Ruffin, KE Thompson, H Corvol, L Guillot
BMC Research Notes 2019

← Previous 1 2 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts

Picked up by 1 news outlets
Posted by 11 X users
57 readers on Mendeley
See more details